| Autor: |
Ming‐Zhu Liu, Shuo‐Gui Fang, Wei Huang, Han‐Yu Wang, Yun‐Ming Tian, Run‐Da Huang, Zhuang Sun, Chong Zhao, Tai‐Xiang Lu, Ying Huang, Fei Han |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Cancer Medicine, Vol 8, Iss 10, Pp 4633-4643 (2019) |
| Druh dokumentu: |
article |
| ISSN: |
2045-7634 |
| DOI: |
10.1002/cam4.2339 |
| Popis: |
Abstract Purpose To define the clinical characteristics and prognostic value of pre‐retreatment plasma Epstein‐Barr virus (EBV) DNA, we investigated EBV status in locoregional recurrent nasopharyngeal carcinoma (lrNPC) patients. Methods Between April 2008 and August 2016, the data of patients with nonmetastatic lrNPC were retrospectively reviewed. The survival indexes of patients between different pre‐retreatment EBV status groups were compared. Results A total of 401 patients with nonmetastatic lrNPC were enrolled, and 197 (49.1%) patients had detectable pre‐retreatment plasma EBV DNA. Treatment included radiotherapy alone (n = 37 patients), surgery alone (n = 105), radiotherapy (n = 208), surgery combined with radiotherapy (n = 20), chemotherapy and targeted therapy (n = 31). Median follow‐up was 32 months. The 3‐year locoregional relapse‐free survival (LRRFS), distant metastasis‐free survival (DMFS), and overall survival (OS) rates for the entire cohort were 64.8%, 89.4%, and 58.8%, respectively. The estimated 3‐year LRRFS, DMFS, and OS rates for the pre EBV‐positive group vs the pre EBV‐negative group were 54.2% vs 75.0% (P 0.05). In terms of long‐term toxic and side effects, the incidence of radioactive temporal lobe injury in the radiotherapy group was higher than that in the surgery group (35.3% vs 8.2%, P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
